secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001493152-24-026924
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lixte Biotechnology switches director compensation from cash to stock options for Q2-Q4 2024 to preserve cash
--------------------------------------------------------------------------------

- Director Rene Bernards agrees to receive equity compensation instead of cash starting Q2 2024, aligning with other non-officer directors.
- Board Compensation Plan amended: non-officer directors will receive stock options for Q2, Q3, Q4 2024 in lieu of cash.
- Options vest immediately, expire in 5 years; exercise price based on quarter-end closing market price.
- Change intended to preserve cash; Board and Compensation Committee may extend beyond Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/0001493152-24-026924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224026924/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-026924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer